BioPharma Credit PLC (BPCR) — Long-term Investment Intensity
BioPharma Credit PLC (BPCR) has a Long-term Investment Intensity of 96.9% as of December 2024. Long-term investments of $1.16 Billion represent 96.9% of total assets of $1.20 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check cash flow reinvestment rate of BioPharma Credit PLC to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
BioPharma Credit PLC Long-term Investment Intensity (2017–2024)
This chart shows how BioPharma Credit PLC's Long-term Investment Intensity has evolved across 8 annual periods from 2017 to 2024. As of December 2024, the intensity stands at 96.9%, reflecting long-term investments of $1.16 Billion against total assets of $1.20 Billion USD. Explore BioPharma Credit PLC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for BioPharma Credit PLC (2017–2024)
The table below presents the year-by-year Long-term Investment Intensity for BioPharma Credit PLC from 2017 to 2024, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see BioPharma Credit PLC (BPCR) market capitalisation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 96.9% | $1.16 Billion | $1.20 Billion | ▲ +8.3 pp |
| 2023 | 88.5% | $1.20 Billion | $1.36 Billion | ▼ -1.2 pp |
| 2022 | 89.7% | $1.22 Billion | $1.36 Billion | ▼ -2.7 pp |
| 2021 | 92.4% | $1.27 Billion | $1.37 Billion | ▲ +6.3 pp |
| 2020 | 86.1% | $1.19 Billion | $1.39 Billion | ▲ +8.0 pp |
| 2019 | 78.1% | $1.12 Billion | $1.43 Billion | ▲ +5.8 pp |
| 2018 | 72.3% | $1.01 Billion | $1.39 Billion | ▲ +10.7 pp |
| 2017 | 61.5% | $569.63 Million | $925.49 Million | — |